Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Butterfly Network, Inc.BFLY · Entity 4467 | EVP, CFO & COO | May 05, 2025 | May 07, 2025 |
| MYOMO, INC.MYO · Entity 7135 | Director | June 25, 2026 | June 26, 2026 |
| TELA Bio, Inc.TELA · Entity 7381 | Director · Chief Executive Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Butterfly Network, Inc.
Report date May 05, 2025 · Filed May 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,919,274 |
Reported balance
After 2025-05-05 transaction · row 1
1 source rowRow 1 · 2025-05-05 · Sale · Disposed 65,456 · Balance 2,919,274 F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.175 to $2.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.175 to $2.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
MYOMO, INC.
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 210,458 |
Reported balance
After 2026-06-25 transaction · row 1
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 78,704 · Balance 210,458 F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four quarterly installments beginning on September 9, 2026. The Reporting Person has elected to defer the receipt of common stock upon the vesting of the RSUs until the earlier of (i) the date that is thirty (30) days following the date of termination of service and (ii) the date of a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four quarterly installments beginning on September 9, 2026. The Reporting Person has elected to defer the receipt of common stock upon the vesting of the RSUs until the earlier of (i) the date that is thirty (30) days following the date of termination of service and (ii) the date of a change in control.
TELA Bio, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 532,500 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Purchase · Acquired 12,500 · Balance 532,500 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6504 to $0.6749. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6504 to $0.6749. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOTELEMETRY, INC.
Report date February 09, 2021 · Filed February 12, 2021
Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 1
1 source rowRow 1 · 2021-02-09 · Disposition to issuer · Disposed 49,947 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash (the "Offer Price"), less any applicable withholding taxes. F2: Includes 21,390 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive the Offer Price, less any applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.68 · Expires 2024-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-09 · Disposition to issuer · Disposed 23,578 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2025-02-16 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-09 · Disposition to issuer · Disposed 29,040 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.57 · Expires 2026-02-15 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-02-09 · Disposition to issuer · Disposed 22,455 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.65 · Expires 2027-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-02-09 · Disposition to issuer · Disposed 10,675 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.35 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-02-09 · Disposition to issuer · Disposed 18,991 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.22 · Expires 2030-02-17 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-02-09 · Disposition to issuer · Disposed 10,634 · Balance 0 F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-02-09 · Disposition to issuer · Disposed 7,977 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-14 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-02-09 · Disposition to issuer · Disposed 1,987 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-02-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-02-09 · Disposition to issuer · Disposed 6,426 · Balance 0 F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash (the "Offer Price"), less any applicable withholding taxes.
F2: Includes 21,390 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive the Offer Price, less any applicable withholding taxes.
F3: Per the terms of the Merger Agreement, each stock option that was outstanding and unexercised as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of shares of Company common stock subject to such stock option immediately prior to the Effective Time, and (ii) the excess, if any, of the Offer Price over the exercise price per share of such stock option, less applicable withholding taxes.
F4: Per the terms of the Merger Agreement, each performance stock unit ("PSU") that was outstanding as of the Effective Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive cash equal to the product of (i) the total number of shares of Company common stock subject to such PSU that would have vested if the applicable performance period ended immediately prior to the Effective Time (assuming that any applicable performance conditions were deemed to be achieved at the target performance level), multiplied by (ii) the Offer Price, less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 28,194 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · derivative · entry 10 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,790 Underlying: Common Stock · 28,194 shares Expires 2022-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock options vested in four equal annual installments, which began on December 31, 2012. The options were fully exercisable as of December 31, 2015. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 28,194 | $70.00 | $1,973,580.00 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · nonDerivative · entry 5 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,561 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.11, inclusive. Read SEC document |
| January 28, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 28,194 | $2.80 | $78,943.20 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · nonDerivative · entry 4 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 26,465 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · derivative · entry 9 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,984 Underlying: Common Stock · 26,465 shares Expires 2022-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock options vested in four equal annual installments, which began on December 31, 2012. The options were fully exercisable as of December 31, 2015. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 38,524 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · derivative · entry 8 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,524 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vested in four equal annual installments, which began on December 31, 2013. The options were fully exercisable as of December 31, 2016. F5 · balance_after: The reporting person's Form 4 filed on February 21, 2012, reporting this grant of options overreported the options by 748 shares. Therefore, the Form 4 filed on January 23, 2019, overreported 748 shares in Column 9. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 64,989 | $70.09 | $4,555,079.01 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · nonDerivative · entry 3 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,561 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.66, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and footnote 3 to this Form 4. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 26,465 | $2.80 | $74,102.00 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:29 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 38,524 | $2.54 | $97,850.96 |
DisclosureSEC source: 0001574774-19-000005 · wf-form4_154879733744732.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 23, 2019 02:50 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,236 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001574774-19-000001 · wf-form4_154821179979074.xml · derivative · entry 3 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,272 Underlying: Common Stock · 8,236 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vested in four equal annual installments, which began on December 31, 2013. The options were fully exercisable as of December 31, 2016. Read SEC document |
| January 17, 2019 Filed Jan 23, 2019 02:50 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 8,236 | $70.01 | $576,602.36 |
DisclosureSEC source: 0001574774-19-000001 · wf-form4_154821179979074.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,561 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.25, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 17, 2019 Filed Jan 23, 2019 02:50 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 8,236 | $2.54 | $20,919.44 |
DisclosureSEC source: 0001574774-19-000001 · wf-form4_154821179979074.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 21,405 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001574774-18-000030 · wf-form4_152546615103148.xml · derivative · entry 5 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,405 shares Expires 2021-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vested in four equal annual installments which began on March 4, 2012. The options were fully exercisable as of March 4, 2015. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001574774-18-000030 · wf-form4_152546615103148.xml · derivative · entry 4 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vested in four equal annual installments which began on December 31, 2011. The options were fully exercisable as of December 31, 2014. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 36,405 | $39.62 | $1,442,366.10 |
DisclosureSEC source: 0001574774-18-000030 · wf-form4_152546615103148.xml · nonDerivative · entry 3 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,561 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $39.30 to $40.15, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 21,405 | $4.67 | $99,961.35 |
DisclosureSEC source: 0001574774-18-000030 · wf-form4_152546615103148.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 36,405 | $4.67 | $170,011.35 |
DisclosureSEC source: 0001574774-18-000030 · wf-form4_152546615103148.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed May 8, 2018 20:18 UTC Amendment | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 36,405 | $4.67 | $170,011.35 |
DisclosureSEC source: 0001574774-18-000032 · wf-form4a_152581062961331.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person filed a Form 4 on May 4, 2018, which reported the receipt of 21,405 and 36,405 shares of common stock in connection with the exercise of options. The 21,405 shares of common stock were included in the 36,405 shares. Therefore, the securities beneficially owned following the transaction reported 21,405 more shares than should have been reported. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,570 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · derivative · entry 9 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,570 shares Expires 2020-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options vested in four equal annual installments which began on May 10, 2011. The options were fully exercisable as of May 10, 2014. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · derivative · entry 8 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vested in four equal annual installments which began on January 22, 2011. The options were fully exercisable as of January 22, 2014. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · derivative · entry 7 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vested in four equal annual installments which began on August 12, 2010. The options were fully exercisable as of August 12, 2013. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · derivative · entry 6 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 65,570 | $38.03 | $2,493,627.10 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · nonDerivative · entry 5 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.00 to $38.65, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 5,570 | $8.79 | $48,960.30 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · nonDerivative · entry 4 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 10,000 | $6.43 | $64,300.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · nonDerivative · entry 3 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 10,000 | $6.95 | $69,500.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 21:48 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 40,000 | $17.44 | $697,600.00 |
DisclosureSEC source: 0001574774-18-000027 · wf-form4_152486563801346.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 21:12 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Tax withholdingCommon Stock | 7,861 | $33.67 | $264,679.87 |
DisclosureSEC source: 0001574774-18-000008 · wf-form4_151924754986597.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,156 F1 · shares: Represents shares withheld to cover taxes in connection with the reporting person's February 16, 2015, RSU Grant. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:22 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantStock Options (Right to Buy) · Derivative | 18,991 | $0.00 Strike: $33.35 | $0.00 |
DisclosureSEC source: 0001574774-18-000005 · wf-form4_151881612714334.xml · derivative · entry 2 Getz Heather C · CIK 0001481485 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,991 Underlying: Common Stock · 18,991 shares Expires 2028-02-14 F2 · derivative.exercise_date: The options shall vest in equal amounts on each of the first four anniversaries of the grant date, provided that the option holder remains in continuous service through the applicable vesting date. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:22 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantCommon Stock | 7,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001574774-18-000005 · wf-form4_151881612714334.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,017 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units (RSUs) awarded to the Reporting Person. The RSUs will vest in full on the third anniversary of the grant date, subject to accelerated vesting upon certain terminations of employment following certain corporate transactions involving the Issuer. The shares of common stock underlying the RSUs will be issued when the RSUs vest. Read SEC document |
| February 15, 2017 Filed Feb 15, 2017 23:33 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Tax withholdingCommon Stock | 6,551 | $24.65 | $161,482.15 |
DisclosureSEC source: 0001209191-17-011212 · doc4.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,040 F2 · shares: Represents shares withheld to cover taxes in connection with the reporting person's February 14, 2014 RSU Grant. F3 · price: Closing price of the Company's common stock on February 14, 2017 Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:33 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantStock Options · Derivative | 10,675 | $0.00 Strike: $24.65 | $0.00 |
DisclosureSEC source: 0001209191-17-011212 · doc4.xml · derivative · entry 3 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,675 Underlying: Common Stock · 10,675 shares Expires 2027-02-14 F4 · derivative.exercise_date: The shares shall vest at the rate of 25% on December 31 and on each of the first, second, and third anniversaries of the Vesting Commencement Date, provided that the Option holder remains in Continuous Service through the applicable vesting date. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:33 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | GrantCommon Stock | 6,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011212 · doc4.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,591 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units (RSUs) awarded to the Reporting Person. The RSUs will vest in full on the third anniversary of the grant date, subject to accelerated vesting upon certain terminations of employment following certain corporate transactions involving the Issuer. The shares of common stock underlying the RSUs will be issued when the RSUs vest. Read SEC document |
| September 13, 2016 Filed Sep 13, 2016 21:33 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 5,866 | $18.23 | $106,937.18 |
DisclosureSEC source: 0001209191-16-141214 · doc4.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,293 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.66, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 12:49 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 2,979 | $18.10 | $53,919.90 |
DisclosureSEC source: 0001209191-16-140857 · doc4.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,159 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.25, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 5,712 | $18.52 | $105,786.24 |
DisclosureSEC source: 0001104659-16-143556 · a4.xml · nonDerivative · entry 3 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,138 F4 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.31 to $18.63, inclusive. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 6,686 | $18.29 | $122,286.94 |
DisclosureSEC source: 0001104659-16-143556 · a4.xml · nonDerivative · entry 2 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,850 F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.90, inclusive. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 22:36 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 6,547 | $18.75 | $122,756.25 |
DisclosureSEC source: 0001104659-16-143556 · a4.xml · nonDerivative · entry 1 Getz Heather C · CIK 0001481485 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.60 to $18.91, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.